Tag: MinuteClinic

CVS Delivers A Strong 2015 And Presents A Compelling Buying Opportunity

Posted on by Noah Kiedrowski

Noah Kiedrowski - INO.com Contributor - Biotech


Introduction

CVS Health Corporation (NYSE:CVS) has just capped off a fantastic 2015 performance in several metrics (EPS growth, revenue, dividends, share buybacks and acquisitions) that drive shareholder value. As 2016 begins, CVS presents a compelling investment opportunity in the healthcare space. This premise is based on the fact that CVS has been highly acquisitive, continues to deliver robust growth, growing its dividends over time and has an aggressive share buyback program. CVS recently reported a record year in 2015 and continues to drive and position itself for long-term success. With its recent acquisitions and partnerships, specifically, the acquisition Target’s pharmacies and Omnicare will significantly expand its footprint and ability to dispense prescriptions to the general public and in assisted living and long-term care facilities that serve the senior patient population. As the United States continues to absorb an aging population alongside growing overall healthcare costs, more specifically prescription drug costs, CVS looks poised to benefit and continue to outperform the broader market. The most recent earnings report, a record year in 2015 with its rise in its 2016 outlook and a 21% boost in its dividend payout underscores this premise. I content that CVS will continue to deliver continued growth and positioning for long-term success to drive shareholder value. Continue reading "CVS Delivers A Strong 2015 And Presents A Compelling Buying Opportunity" →

CVS Boosts Dividend By 21% And Raises 2016 Outlook

Posted on by Noah Kiedrowski

Noah Kiedrowski - INO.com Contributor - Biotech


Introduction

I have posted that CVS presented a compelling investment opportunity in the healthcare space. This premise was rooted in the fact that CVS has been highly acquisitive, continuous robust growth rate, growing its dividends over time and has an aggressive share buyback program. CVS recently reported robust earnings and continued to drive and position itself for long-term success. With its recent acquisitions and partnerships, specifically, the acquisition Target’s pharmacies and Omnicare will significantly expand its footprint and ability to dispense prescriptions to the general public and in assisted living and long-term care facilities that serve the senior patient population. As the United States continues to absorb an aging population alongside growing overall healthcare costs, more specifically prescription drug costs, CVS looks poised to benefit and continue to outperform the broader market. The most recent earnings report, rise in its 2016 outlook and a 21% boost in its dividend payout underscores this premise. I content that CVS will continue to deliver continued growth and positioning for long-term success. Continue reading "CVS Boosts Dividend By 21% And Raises 2016 Outlook" →

This Healthcare Juggernaut Continues To Deliver

Posted on by Noah Kiedrowski

Noah Kiedrowski - INO.com Contributor - Biotech


Introduction

I posited that CVS presented a compelling investment opportunity in the healthcare space. This premise was rooted in the fact that CVS has been highly acquisitive, robust growth rate, growing its dividends over time and has an aggressive share buyback program in place. CVS recently reported robust earnings and continued to drive and position itself for long-term success. With its recent acquisitions and partnerships, specifically the acquisition Target’s pharmacies and Omnicare will significantly expand its footprint and ability to dispense prescriptions to the general public and in assisted living and long-term care facilities that serve the senior patient population. As the United States continues to absorb an ageing population alongside growing overall healthcare costs, more specifically prescription drug costs, CVS looks poised to benefit and continue to outperform the broader market. The most recent earnings report underscores this premise and CVS continues to deliver continued growth and positioning for long-term success.

2015 Q3 Earnings

Recently, CVS reported strong earnings for the quarter ending September 30th, 2015. Net revenue increased more than 10% to $36.8 billion while adjusted EPS increased to $1.28 or 11.5% as compared to the prior year quarter. Continue reading "This Healthcare Juggernaut Continues To Deliver" →

CVS - An Undervalued Healthcare Juggernaut

Posted on by Noah Kiedrowski

Noah Kiedrowski - INO.com Contributor - Biotech


Introduction

CVS presents a compelling investment opportunity in the healthcare space. CVS has been highly acquisitive, growing its dividends over time and has an aggressive share buyback program in place. CVS is currently the largest prescription drug dispenser and the second-largest pharmacy benefits manager. Along with its recent acquisitions and partnerships will significantly expand its footprint and ability to dispense prescriptions to the general public and in assisted living and long-term care facilities that serve the senior patient population. As the United States continues to absorb an aging population alongside growing overall healthcare costs, more specifically prescription drug costs, CVS looks poised to benefit and continue to outperform the broader market.

CVS Health – A true healthcare company

Approximately one year ago, CVS announced that it had removed all tobacco products from its stores nationwide and would no longer sell any tobacco related products to its customers. This was a bold move as CVS has become the trailblazer in establishing itself as a true health oriented company. Ceasing tobacco sales negatively impacted overall sales, however, this move established itself as a true healthcare focused company. "One year ago, we stopped selling tobacco products because it conflicted with our purpose of helping people on their path to better health," said Troyen A. Brennan, M.D., M.P.H., Chief Medical Officer, CVS Health. "Today, we are excited to release new data demonstrating the positive impact our decision has had on public health overall as shown by a measurable decrease in the number of cigarette purchases across all retailers." Personally, I like companies that stand behind their name and practice what they advocate and, in this case, it's promoting overall health and wellbeing. Continue reading "CVS - An Undervalued Healthcare Juggernaut" →

Drugstore Wars: Walgreen Vs. CVS

Posted on by admin

I hope I'm not dating myself too much, but I remember when the neighborhood chain drugstore was almost a one-stop shop for human needs.

For example, you dropped off your film to get developed. You could get the ointment for that embarrassing itch. You could even get a BLT and some fries. (Not necessarily in that order.)

The BLTs and fries are long gone, but the chain drugstore on the neighborhood corner has continued to evolve and embed itself into our daily lives. And it will continue to do so in an even bigger way going forward.

By far, the two biggest players in the drugstore space are Walgreen Co. (NYSE: WAG) and CVS Caremark (NYSE: CVS). If two-thirds of the Earth is covered by water, the remaining third is covered by these two companies. But which stock makes the most sense for your portfolio? Continue reading "Drugstore Wars: Walgreen Vs. CVS" →